NSPR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NSPR News | Roxom Stocks

NS

Volume

90.27K

Next Earnings

November 3rd

Loading chart

NS

NSPRInspireMD, Inc.

NSPR

Pay with—

Available Balance0.00

NS

Mkt Cap

$22.5M

Volume

90.27K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 MillionInspireMD amended Series J and K warrants affecting approximately 14.3 million shares, aligning the exercise trigger with anticipated FDA approval of CGuard Prime 80 cm expected in Q4 2026. The amendments could provide up to $11 million in gross proceeds to fund the commercial launch of the TCAR product, which targets an addressable market of over 35,000 annual procedures in the U.S.GlobeNewswire Inc. · Sep 21, 2026

InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR ProceduresInspireMD announced the first patient enrollment in the CGUARDIANS III pivotal study for its SwitchGuard neuro protection system used with CGuard Prime 80 cm stent in TCAR procedures. The prospective, multi-center study will enroll approximately 103 subjects to evaluate safety and efficacy for treating carotid artery stenosis. The company projects 70,000 TCAR procedures annually in the U.S. by 2030.GlobeNewswire Inc. · Jun 8, 2026

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)InspireMD's Compensation Committee approved inducement grants of 36,118 restricted shares to one new non-executive employee on January 14, 2026, under the company's 2024 Inducement Plan in compliance with Nasdaq rules. The shares vest over three years subject to continued employment.GlobeNewswire Inc. · Jan 20, 2026

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)InspireMD announced that its C-GUARDIANS pivotal trial results have been published in JACC, demonstrating that the CGuard® Prime Carotid Stent System achieved the lowest 30-day and 1-year major adverse event rates in carotid stenting studies, with a 30-day DSMI rate of 0.95% and 1-year ipsilateral stroke rate of 1.93%. The trial enrolled 316 patients including 25% symptomatic cases, showing strong safety and efficacy data for carotid artery stenosis treatment.GlobeNewswire Inc. · Jan 12, 2026

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)InspireMD granted 122,054 shares of restricted stock to eight new non-executive employees under its 2024 Inducement Plan, with shares vesting over a three-year period.GlobeNewswire Inc. · Nov 21, 2025

InspireMD Reports Third Quarter 2025 Financial ResultsInspireMD reported Q3 2025 financial results, highlighting a 39% revenue increase to $2.5 million, successful U.S. commercial launch of CGuard Prime carotid stent system, and continued global market expansion despite increased operating expenses.GlobeNewswire Inc. · Nov 4, 2025

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)InspireMD granted 40,513 shares of restricted stock to three new non-executive employees under its 2024 Inducement Plan, with shares vesting over a three-year period.GlobeNewswire Inc. · Oct 8, 2025

Global Embolic Protection Devices Market Set to Experience Unprecedented Growth at a CAGR of ~8% by 2032 | DelveInsightThe global embolic protection devices market is projected to grow at an 8% CAGR by 2032, driven by increasing cardiovascular and neurovascular disease prevalence, minimally invasive surgical trends, and technological innovations.GlobeNewswire Inc. · Aug 13, 2025

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of StrokeInspireMD, a medical device company, has received CE Mark approval under the European Medical Device Regulation (MDR) for its CGuard® Prime Embolic Prevention System (EPS), a carotid stent designed to prevent stroke.GlobeNewswire Inc. · Jun 13, 2025

InspireMD Reports First Quarter 2025 Financial ResultsInspireMD, a developer of the CGuard Prime carotid stent system, reported its Q1 2025 financial results. The company saw a 1.2% increase in revenue, but a significant increase in operating expenses, leading to a net loss of $11.2 million. The company remains optimistic about the upcoming FDA approval of its CGuard Prime system.GlobeNewswire Inc. · May 9, 2025

to start trading

NS

NSPRInspireMD, Inc.

NSPR

Pay with—

Available Balance0.00

Your PositionYou don't own any NSPR yet.

Related Tickers

Earnings